» Articles » PMID: 34073735

Validation of Inactivation Methods for Arenaviruses

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2021 Jun 2
PMID 34073735
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Several of the human-pathogenic arenaviruses cause hemorrhagic fever and have to be handled under biosafety level 4 conditions, including Lassa virus. Rapid and safe inactivation of specimens containing these viruses is fundamental to enable downstream processing for diagnostics or research under lower biosafety conditions. We established a protocol to test the efficacy of inactivation methods using the low-pathogenic Morogoro arenavirus as surrogate for the related highly pathogenic viruses. As the validation of chemical inactivation methods in cell culture systems is difficult due to cell toxicity of commonly used chemicals, we employed filter devices to remove the chemical and concentrate the virus after inactivation and before inoculation into cell culture. Viral replication in the cells was monitored over 4 weeks by using indirect immunofluorescence and immunofocus assay. The performance of the protocol was verified using published inactivation methods including chemicals and heat. Ten additional methods to inactivate virus in infected cells or cell culture supernatant were validated and shown to reduce virus titers to undetectable levels. In summary, we provide a robust protocol for the validation of chemical and physical inactivation of arenaviruses in cell culture, which can be readily adapted to different inactivation methods and specimen matrices.

Citing Articles

Efficacy of microbicidal actives and formulations for inactivation of Lassa virus in suspension.

Cutts T, Nims R, Rubino J, McKinney J, Kuhn J, Ijaz M Sci Rep. 2023; 13(1):12983.

PMID: 37563252 PMC: 10415271. DOI: 10.1038/s41598-023-38954-5.


Art of the Kill: Designing and Testing Viral Inactivation Procedures for Highly Pathogenic Negative Sense RNA Viruses.

Olejnik J, Hume A, Ross S, Scoon W, Seitz S, White M Pathogens. 2023; 12(7).

PMID: 37513799 PMC: 10386221. DOI: 10.3390/pathogens12070952.


A validated protocol to UV-inactivate SARS-CoV-2 and herpesvirus-infected cells.

Soh T, Pfefferle S, Wurr S, von Possel R, Oestereich L, Rieger T PLoS One. 2023; 18(5):e0274065.

PMID: 37163509 PMC: 10171616. DOI: 10.1371/journal.pone.0274065.


Understanding Host-Virus Interactions: Assessment of Innate Immune Responses in Cells after Arenavirus Infection.

Brinkmann N, Hoffmann C, Wurr S, Pallasch E, Hinzmann J, Ostermann E Viruses. 2022; 14(9).

PMID: 36146793 PMC: 9506377. DOI: 10.3390/v14091986.


Inactivation Methods for Experimental Nipah Virus Infection.

Widerspick L, Vazquez C, Niemetz L, Heung M, Olal C, Bencsik A Viruses. 2022; 14(5).

PMID: 35632791 PMC: 9145063. DOI: 10.3390/v14051052.

References
1.
ELLIOTT L, McCormick J, Johnson K . Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol. 1982; 16(4):704-8. PMC: 272450. DOI: 10.1128/jcm.16.4.704-708.1982. View

2.
Mitchell S, McCormick J . Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses. J Clin Microbiol. 1984; 20(3):486-9. PMC: 271356. DOI: 10.1128/jcm.20.3.486-489.1984. View

3.
Gunther S, Asper M, Roser C, Luna L, Drosten C, Becker-Ziaja B . Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro. Antiviral Res. 2004; 63(3):209-15. PMC: 7126008. DOI: 10.1016/j.antiviral.2004.05.001. View

4.
Roberts P . Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII. Biologicals. 2008; 36(5):330-5. DOI: 10.1016/j.biologicals.2008.06.002. View

5.
Gunther S, Hoofd G, Charrel R, Roser C, Becker-Ziaja B, Lloyd G . Mopeia virus-related arenavirus in natal multimammate mice, Morogoro, Tanzania. Emerg Infect Dis. 2009; 15(12):2008-12. PMC: 3044542. DOI: 10.3201/eid1512.090864. View